Iza-bren Doubles PFS Post-TKI but OS and Safety Detail Lag Behind

Iza-Bren Doubles PFS in EGFR-Mutated NSCLC Phase 3 Trial

SystImmune and Bristol Myers Squibb announced positive results from the Phase 3 PANKU-Lung01 study for izalontamab brengitecan (iza-bren) in patients with EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with an EGFR TKI. Iza-bren, an investigational dual-targeting EGFRxHER3 bispecific antibody-drug conjugate (ADC), significantly improved the primary endpoint of progression-free survival (PFS) compared to platinum-based chemotherapy (PBC). The median PFS was 11.1 months for iza-bren versus 5.7 months for PBC (HR: 0.40; 95% CI: 0.31-0.51; p<0.0001). The drug also demonstrated a manageable safety profile and favorable trends in secondary endpoints, including objective response rate.

• The Phase 3 PANKU-Lung01 study showed that iza-bren achieved a median progression-free survival (PFS) of 11.1 months, nearly doubling the 5.7 months observed with platinum-based chemotherapy. This statistically significant improvement (HR: 0.40; 95% CI: 0.31-0.51; p<0.0001) underscores iza-bren's potential to provide a substantial clinical benefit for patients facing disease progression after prior EGFR TKI therapy.
• Beyond the primary endpoint, iza-bren demonstrated superior efficacy in key secondary endpoints. The confirmed objective response rate (cORR) was 60.2% for iza-bren compared to 34.5% for PBC, and the median duration of response (mDOR) was 10.4 months versus 5.7 months, respectively. While overall survival data were immature, a favorable trend was observed, further supporting iza-bren's potential.
• Iza-bren exhibited a manageable safety profile consistent with previous observations, with no new safety signals identified. Grade ≥3 treatment-related adverse events were predominantly hematologic and manageable with standard supportive care, leading to a low discontinuation rate of 1.9% due to TRAEs. This favorable safety profile is crucial for a treatment intended for patients with limited options.
• These positive results position iza-bren as a potential game-changer for EGFR-mutated NSCLC patients who have progressed on EGFR TKI therapy, addressing a significant unmet medical need. The drug has also shown clinical benefit across five distinct tumor types and received Breakthrough Therapy Designation from the U.S. FDA for previously-treated advanced EGFR-mutated NSCLC, highlighting its broad therapeutic promise.

Addressing the Unmet Need in Post-TKI EGFR-mutated NSCLC

Acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is inevitable in EGFR-mutant non-small cell lung cancer (NSCLC), with osimertinib resistance developing in 1 to 2 years and AZD9291 showing a median duration of response of 9 months [range, 9-11 months] before progression. Resistance reflects dynamic clonal heterogeneity with accumulation, over time and across different disease sites, of subclonal genetic mutations and nongenetic adaptations.

• Loss and depopulation of EGFR-mutant clones: AZD9291-resistant tumors showed depopulation of EGFR-mutant clones to below 1% (baseline, 14%-36%) in three patients with progression, including one with the loss of EGFR-double mutant clones.

• Secondary EGFR alterations conferring TKI-specific resistance: The occurrence of EGFR T790M is associated with resistance to gefitinib, erlotinib, and afatinib, while EGFR C797S causes osimertinib to lose activity, with EGFR amplification and T790M mutation also reported as acquired resistance mechanisms during EGFR TKI treatment.

• Bypass pathway activation: Resistance involves focal fibroblast growth factor receptor 1 (FGFR1) amplification, MET amplification and MET exon 15-20 duplication suggesting MET bypass activation, insulin-like growth factor (IGF)/IGF1 receptor activation, and IGF2 autocrine-mediated IGF1R pathway activation, including increased IGF2 expression in patients who met the established clinical definition of acquired resistance.

• Histologic transformation and ligand-dependent activation: Two AZD9291-resistant cases were accompanied by transformation to small-cell carcinoma and focal FGFR1 amplification, respectively, while EGFR-mutant clones remained and the EGFR ligand was overexpressed in one patient with focal progression to AZD9291, consistent with EGFR ligand-dependent activation.

• Dual resistance to combination EGFR-TKI and Met-TKI exposure and limits of genomic detection: Met-amplified gefitinib-resistant cells acquire dual resistance to inhibition of EGFR and Met tyrosine kinase activities without secondary mutation of EGFR T790M or a Met mutation, via IGF-binding protein 3-maintained Met expression, HSP90-associated Met amplification protecting Met from degradation, and SET and MYND domain-containing 3 (SMYD3)-mediated Met transcription, while IGF2 autocrine-mediated IGF1R activation was not detected by previously performed NGS.

PANKU-Lung01: Design, Endpoints, and Pivotal Results

Key trials in EGFR TKI-pretreated EGFR-mutated NSCLC evaluate third-generation EGFR TKIs and post-osimertinib combinations in populations with acquired resistance, including EGFR T790M mutation. Designs include prospective single-arm phase I/II trials and retrospective real-world cohorts, with endpoints focused on response rate, progression-free survival, overall survival, and safety.

Iza-Bren's Broad Potential Across Multiple Tumor Types

The knowledge base does not have sufficient information to answer this question.

A New Horizon for Post-TKI EGFR-Mutated NSCLC

The recent announcement regarding izalontamab brengitecan (iza-bren) marks a significant moment for patients battling EGFR-mutated non-small cell lung cancer (NSCLC) who have progressed after initial EGFR TKI therapy. This patient cohort faces a challenging prognosis, with current treatment options often limited to less effective or more toxic chemotherapy regimens. The Phase 3 PANKU-Lung01 study's impressive results, demonstrating a median progression-free survival of 11.1 months for iza-bren compared to 5.7 months for platinum-based chemotherapy, offer a beacon of hope. This substantial improvement, coupled with a hazard ratio of 0.40, underscores the drug's potential to redefine the standard of care in this critical second-line setting.

Iza-bren's mechanism as a first-in-class EGFRxHER3 bispecific antibody-drug conjugate is particularly noteworthy. By simultaneously targeting two key receptors involved in cancer cell proliferation and survival, it aims to overcome resistance pathways that frequently emerge after TKI treatment. This innovative approach, previously hinted at by promising Phase 1/2 data showing robust antitumor activity and a manageable safety profile, now has strong Phase 3 validation.

However, as with any novel therapy, a nuanced perspective is essential. While the safety profile is described as manageable, earlier studies indicated a high incidence of treatment-related adverse events, predominantly hematologic, which will necessitate proactive management strategies in clinical practice. The potential for interstitial lung disease, though rare in earlier phases, also warrants careful monitoring given its association with ADCs and EGFR-targeting agents. Furthermore, while PFS is a critical endpoint, the full long-term overall survival benefit will be a key determinant of iza-bren's ultimate impact and market penetration. The successful integration of iza-bren into treatment algorithms will depend on balancing its significant efficacy gains with diligent adverse event management and continued data maturation.